Vascular

Allograft Bio-Implants for Vascular Procedures

AngioGRAFT® cryopreserved allograft vessels are the natural choice for managing vascular reconstruction.

LifeNet Health grafts consistently perform as they should, allowing medical professionals to focus on the procedure, and patients to focus on healing. Year after year, this dedication to quality is validated internally and vetted by health-care organizations and industry partners, as well as government and industry regulators.
 

Our comprehensive portfolio allows customers to get more solutions from a single source – freeing time and resources to focus on providing the highest quality patient care. Our responsive client service department is available 24 hours per day and our Specialists are available to consult with surgeons or conduct in-service programs for operating room staff on allograft preparation.


Peripheral Vascular Disease (PVD)/Critical Limb IschemiaPeripheral Vascular Disease (PVD)/Critical Limb Ischemia

Cryopreserved allografts provide a natural solution to help treat critical limb ischemia. Allografts closely resemble native tissue, making them compliant, flexible and easy to handle. Allografts also are naturally resistant to infection1,2,3, avoid donor site morbidity, and are an ideal conduit in cases where use of autologous vessels is not possible.
Aortoiliac DiseaseAortoiliac Disease
Aortoiliac disease is one of the most difficult to treat conditions that a surgeon faces. Whether due to a failed synthetic graft, an aortoenteric fistula, or mycotic aneurysm, cryopreserved aortoiliac (AI) grafts provide an ideal solution to the treatment and care of patients with aortoiliac disease.6
AngioGraft AI grafts are unique in that they are the only AI grafts available with pressurized diameter measurements making size matching more accurate potentially reducing time in the OR by eliminating the need to alter the graft to fit the size of the patient’s vasculature.
Coronary Artery DiseaseCoronary Artery Disease
AngioGraft cryopreserved vessels provide a convenient solution that can avoid possible complications of autograft recovery when the patient’s own vessels are not healthy enough, or available for coronary artery bypass graft (CABG) procedures.4,5
Arteriovenous AccessArteriovenous (AV) Access

Following a failed AV fistula, cryopreserved femoral veins and arteries provide an ideal solution to AV access for dialysis. In cases of infection or in patients at a greater risk of infection, allografts can also provide a safer solution due to their natural resistance to infection.1,2,3


REFERENCES:
1. Vardanian et al. Arterial Allograft Allows In-line Reconstruction of Prosthetic Graft Infection with Low Recurrence Rate and Mortality. The American Surgeon October 2009 Vol. 75, No. 10: 1000-1003.
2. Madden et al. Experience with cryopreserved cadaveric femoral vein allografts used for hemodialysis access. Annals of Vascular Surgery 2004; 18: 453-458
3. O’Banion et al. Cryopreserved saphenous vein as a last-ditch conduit for limb salvage. Journal of Vascular Surgery 2017, Volume 66, Number 3: 844-849
4. Harlander-Locke et al. The use of cryopreserved aortoiliac allograft for aortic reconstruction in the United States. Journal of Vascular Surgery, Volume 59, Number 3:669-674
5. Bossi, Tozzi et al. Cryopreserved Human Allografts for the Reconstruction of Aortic and Peripheral Prosthetic Graft Infection, Annals of Vascular Diseases, 2017, Volume 10, Issue 4, Pages 391-397. 2017.
6. Randon et al. Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage. Journal of Vascular Surgery 2010;51:869-77.

 

Description

AngioGRAFT® Femoral Artery and Vein

  • Human tissue-most closely resembles native tissue
  • Resistance to infection
  • Vein allografts are an alternative conduit for patients lacking available autogenous veins
Clinical Application
  • Patients in whom an autologous fistula is not possible
  • Replacing infected AV access grafts or in patients who are at risk of AV access infections
  • Patients with a limited number of AV access sites
  • Peripheral vascular disease
CryopreservedDescriptionSize
FV<21

Femoral Vein

L ≤ 21 cm
FV21-30

Femoral Vein

L = 21-30 cm
FV>30

Femoral Vein

L ≥ 30 cm
FA<21

Femoral Artery

L ≤ 21 cm
FA21-30

Femoral Artery

L = 21-30 cm
FA>30

Femoral Artery

L ≥ 30 cm
Description

AngioGRAFT® Cryopreserved Saphenous Vein

  • Human tissue-most closely resembles native tissue
  • Resistance to infection
  • Vein allografts are an alternative conduit for patients lacking available autogenous veins
Clinical Application
  • Peripheral vascular disease
  • CABG
  • Patients with infected fields or at risk of infection
  • AV access
CryopreservedDescriptionSize
CV21-30

Cryopreserved Saphenous Vein

L = 21-30 cm
CV31-45

Cryopreserved Saphenous Vein

L = 31-45 cm
CV>80

Cryopreserved Saphenous Vein

L > 80 cm
CV46-60

Cryopreserved Saphenous Vein

L = 46-60 cm
CV61-70

Cryopreserved Saphenous Vein

L = 61-70 cm
CV71-80

Cryopreserved Saphenous Vein

L = 71-80 cm
Description

A safe and efficacious alternative to synthetic grafts, in abdominal aortoiliac procedures.

• Allograft tissue most closely resembles the patient’s native tissue
• Convenient: Available in 3 configurations, and measured in both flaccid and pressurized diameter sizing
• Safety: Allografts offer a high resistance to infection1, 2
Clinical Application
• Infected Synthetic Graft Replacement
• Trauma
• Mycotic Aneurysm
• Aortoenteric Fistula
 
 
References
1 Harlander-Locke, M.P., et al., The use of cryopreserved aortoiliac allograft for aortic reconstruction in the United States. J Vasc Surg,
2014. 59(3): p. 669-74.
2 Philpott, JM, and Zemlin, CW. Aortic reconstruction for an infected stent graft with a composite homograft. J Thoracic and
Cardiovascular Surgery, Volume 153, Issue 5, e73-e75.